Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 14/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 7/20 | 0.40 |
| ▸ | CYP26B1 | Q9NR63 | 7/20 | 0.40 |
| ▸ | RXRB | P28702 | 9/20 | 0.40 |
| ▸ | RXRG | P48443 | 7/20 | 0.40 |
| ▸ | RARB | P10826 | 5/20 | 0.40 |
| ▸ | RARG | P13631 | 4/20 | 0.40 |
| ▸ | RARA | P10276 | 3/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7754547 | 0.84 | RXRA (0.41) | RXRACYP26A1CYP26B1RXRBRXRG | |
| SCHEMBL7755847 | 0.75 | CYP26B1 (0.52) | RXRACYP26A1CYP26B1RXRBRXRG | |
| SCHEMBL7755850 | 0.75 | CYP26B1 (0.52) | RXRACYP26A1CYP26B1RXRBRXRG | |
| SCHEMBL7754571 | 0.74 | RXRA (0.56) | RXRACYP26A1CYP26B1RXRBRXRG | |
| SCHEMBL7755889 | 0.73 | RXRA (0.39) | RXRACYP26A1CYP26B1RXRBRXRG | |
| SCHEMBL7789433 | 0.73 | CYP26A1 (0.45) | RXRACYP26A1CYP26B1RXRBRXRG | |
| SCHEMBL7882967 | 0.70 | RARB (0.68) | RXRACYP26A1CYP26B1RXRBRXRG | |
| SCHEMBL7781167 | 0.70 | RXRA (0.48) | RXRACYP26A1CYP26B1RXRBRXRG | |
| SCHEMBL7760265 | 0.68 | RXRA (0.54) | RXRACYP26A1CYP26B1RXRBRXRG | |
| SCHEMBL7756603 | 0.68 | RXRA (0.57) | RXRACYP26A1CYP26B1RXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010034448-A1 | New compounds, their preparation and use | MURRAY ANTHONY (GB) | 2001-10-25 | — | — | US | claimed |
| EP-1077920-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-02-28 | — | — | EP | claimed |
| WO-1999058487-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-11-18 | — | — | WO | claimed |
| US-20010034448-A1 | New compounds, their preparation and use | MURRAY ANTHONY (GB) | 2001-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034448-A1 | New compounds, their preparation and use | GPR119, SLC5A1, SLC5A2 | RXRA 765/4885CYP26A1 585/4885CYP26B1 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.